Juvenile Arthritis News

In patients with juvenile idiopathic arthritis, genicular nerve block achieved “equivalent, longer-term improvement,” after 12 weeks compared with steroid therapy, according to data published in Clinical Rheumatology.

Patients with juvenile idiopathic arthritis who undergo therapy with TNF inhibitors have an outsized risk for later developing psoriasis, and other revelations, led Healio’s coverage of juvenile arthritis in 2022.

An artificial intelligence tool called KIDMATCH may be able to accurately distinguish between MIS-C, Kawasaki disease and other similar febrile diseases, according to data published in the Lancet Digital Health.

The FDA has approved Idacio as the eighth biosimilar to adalimumab, for all eligible indications of the reference product, clearing the way for its U.S. release in 2023 alongside a deluge of other Humira biosimilars.

PHILADELPHIA — Making sense of real-world data and black-box warnings associated with Janus kinase inhibitors can be challenging for rheumatologists hoping to prescribe these medications, according to a presenter at ACR Convergence 2022.

PHILADELPHIA — Patients with juvenile idiopathic arthritis started on conventional synthetic and biologic disease-modifying antirheumatic drug therapy concurrently had better results than patients on other plans, according to data presented here.

A validated prognostic tool using common clinical markers could help clinicians evaluate patients with juvenile idiopathic arthritis for chronic uveitis risk, according to data published in Arthritis & Rheumatology.

It is crucial that patients with juvenile arthritis stay active throughout their childhood for a better chance at building stronger bones, according to DMOS Orthopaedic Centers.

The Pfizer-BioNTech COVID-19 vaccine offers similar protection against the disease in adolescent patients with and without inflammatory or immune rheumatic conditions, according to data published in Rheumatology.

Higher health-related quality of life scores in children with juvenile idiopathic arthritis correspond to higher career- and health-related quality of life scores for their caregivers, according to data published in Pediatric Rheumatology.